Quince Therapeutics, Inc. (QNCX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
QNCX Chart
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript
Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript
Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential
Quince Therapeutics is rated Buy ahead of its pivotal Phase 3 NEAT trial readout in Ataxia-Telangiectasia (A-T) expected mid-Q1 2026. eDSP, QNCX's lead asset, offers chronic corticosteroid delivery with reduced toxicity, targeting a $1B+ orphan market with no approved therapies. The NEAT trial addresses prior design flaws, is 90% powered for statistical significance in 6-9 year-olds, and enjoys strong regulatory alignment.
Quince Therapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JK Jason Kolbert D. Boral Capital | -24,375.15 | $32,336.67 | $22,668.89 | $9,667.78 | 29.9% |
Quince Therapeutics, Inc. (QNCX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Quince Therapeutics, Inc. ever had a stock split?
Quince Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dirk Thye CEO | NASDAQ (NGS) Exchange | 22053A206 CUSIP |
| US Country | 36 Employees | - Last Dividend | 13 Apr 2026 Last Split | 9 May 2019 IPO Date |
Overview
Quince Therapeutics, Inc., originating as Cortexyme, Inc., underwent a rebranding in August 2022 to its current identity. This biopharmaceutical entity, nestled in the scientific hub of South San Francisco, California, has anchored its foundational year back in 2012. Operating within the rigorous and innovation-driven preclinical stage, Quince Therapeutics spearheads the development of precision therapeutics. This noble pursuit concentrates on the realm of debilitating and rare diseases, marking a significant leap towards addressing the complex needs of patients saddled with these conditions.
Products and Services
NOV004: The crown jewel of Quince Therapeutics' innovative efforts is encapsulated in NOV004. This leading compound unveils a new horizon in the treatment landscape, with its identity rooted as a systemically administered bone anabolic peptide. Its design is not just a marvel of bioengineering but a beacon of hope, strategically engineered to target and concentrate precisely at the sites of bone fractures. The therapeutic intention behind NOV004 is manifested through its potential to revolutionize care for patients suffering from bone-related ailments, showcasing Quince Therapeutics' dedication to pioneering breakthroughs in the medical field.
